SCHEMBL14267604

SCHEMBL14267604

CCCC(NC(=O)c1cc(OC)ccc1NS(=O)(=O)c1ccc(C)cc1)c1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 10/20 0.86
CYP2C9 P11712 2/20 0.53
CYP1A2 P05177 1/20 0.53
LMNA P02545 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
TP53 P04637 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP2C19 P33261 1/20 0.46
KEAP1 Q14145 1/20 0.46
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201016 0.93 KCNA5 (1.00) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2
SCHEMBL14267648 0.93 KCNA5 (1.00) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2
SCHEMBL14267603 0.93 KCNA5 (1.00) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2
SCHEMBL4231702 0.88 KCNA5 (0.91) KCNA5LMNASMN1; SMN2TP53ALDH1A1
SCHEMBL4231699 0.88 KCNA5 (0.91) KCNA5LMNASMN1; SMN2TP53ALDH1A1
SCHEMBL14267645 0.83 KCNA5 (0.83) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2
SCHEMBL14267609 0.83 KCNA5 (0.83) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2
SCHEMBL2478556 0.82 KCNA5 (0.80) KCNA5CYP2C9CYP1A2LMNAALDH1A1
SCHEMBL12202105 0.82 KCNA5 (0.80) KCNA5CYP2C9CYP1A2LMNAALDH1A1
SCHEMBL14267592 0.81 KCNA5 (0.74) KCNA5CYP2C9CYP1A2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 KCNA5 10/4885CYP2C9 1109/4885CYP1A2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.